国际妇产科学杂志

国际妇产科学杂志 ›› 2018, Vol. 45 ›› Issue (3): 331-336.

• 论著 • 上一篇    下一篇

子宫内膜癌灶及癌旁组织中LYVE-1、Prox-1表达的临床意义

刘彩艳，张雯雯，吴海霞，申彦，曲芃芃   

  1. 300100  天津市中心妇产科医院妇瘤科（刘彩艳，曲芃芃），妇产科研究所（张雯雯），病理科（吴海霞，申彦）
  • 收稿日期:2017-09-18 修回日期:2018-04-20 出版日期:2018-06-15 发布日期:2018-06-22
  • 通讯作者: 曲芃芃，E-mail: qu.pengpeng@hotmail.com E-mail:qu.pengpeng@hotmail.com
  • 基金资助:
    南开大学药物化学国家重点实验室开发课题（2017015）

The Clinical Significance of Expression of LYVE-1 and Prox-1 in Endometrial Tumor and Paracancer Tissues

LIU Cai-yan, ZHANG Wen-wen, WU Hai-xia, SHEN Yan, QU Peng-peng   

  1. Department of Gynecological Oncology（LIU Cai-yan, QU Peng-peng）, Research Institute of Obstetrics and Gynecology（ZHANG Wen-wen）, Department of Pathology（WU Hai-yan, SHEN Yan）, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300100, China
  • Received:2017-09-18 Revised:2018-04-20 Published:2018-06-15 Online:2018-06-22
  • Contact: QU Peng-peng, E-mａｉｌ： qu.pengpeng@hotmail.com E-mail:qu.pengpeng@hotmail.com

PDF (PC)

6987

摘要： 目的：探讨淋巴管内皮透明质酸受体1（lymphatic vessel endothelial hyaluronan receptor 1，LYVE-1）、同源异型盒基因转录因子1（prospero-related homeobox 1，Prox-1）的表达与子宫内膜癌临床病理特征的关系。方法：选取子宫内膜癌石蜡切片标本57例，留取新鲜子宫内膜癌组织及癌旁组织标本共38例。采用免疫组织化学、蛋白质印迹（Western blotting）、实时荧光定量逆转录聚合酶链反应（Realtime RT-PCR）检测LYVE-1、Prox-1在癌组织及癌旁组织中的表达，分析这2种蛋白在癌组织与癌旁组织中的表达差异与临床病理特征的关系。结果：①免疫组化显示，组织学分级Ⅰ级患者癌灶内的Prox-1阳性表达率高于Ⅱ级、Ⅲ级患者，差异有统计学意义（P＜0.05）；淋巴脉管间隙浸润（lymph vascular space invasion，LVSI）阳性患者癌旁组织的LYVE-1阳性表达率高于LVSI阴性者，差异有统计学意义（P＜0.05）；LVSI阳性、晚期患者子宫内膜癌旁组织Prox-1表达的阳性率升高，与LVSI阴性及早期患者比较差异有统计学意义（P＜0.05）。②Realtime RT-PCR及Western blotting检测显示，相对于无淋巴结转移组的癌旁组织，淋巴结转移组癌旁Prox-1蛋白表达量为1.250 0±0.008 2（P＜0.05），LYVE-1蛋白表达量为1.860 0±0.012 4（P＜0.05）；相对于癌旁组织，淋巴结转移组癌组织中Prox-1 mRNA表达量为0.693±0.083（P＜0.05），LYVE-1 mRNA表达量为0.42±0.16（P＜0.05）。结论：LYVE-1、Prox-1可能是子宫内膜癌淋巴转移的潜在标志物，子宫内膜癌癌旁组织中淋巴管生成可能与淋巴转移有关。

关键词: 淋巴管内皮透明质酸受体1, 同源异型盒基因转录因子1, 子宫内膜癌, 临床病理, 印迹法, 蛋白质, 聚合酶链反应

Abstract: Objective：To analyze the relationship between clinicopathological features and the expression levels of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-l) and prospero-related homeobox 1 (Prox-1) in endometrial carcinoma. Methods: Selected 57 cases of paraffin section specimens and 38 cases fresh tumor tissues and paracancer tissues of endometrial carcinoma. Immunohistochemistry, Western blotting, and Realtime RT-PCR were used to detect the expression of LYVE-1 and Prox-1 in tumor tissues and paracancer tissues. Analysis of the relationship between the expression of these two proteins and the clinicopathological features in tumor tissues and paracancer tissues. Results: ①Immunohistochemical display: The positive expression rate in tumor tissues of Prox-1 in the histologic grade I patients was statistically higher than that of grade Ⅱ and grade Ⅲ patients, the difference was statistically significant（P＜0.05）. The positive expression rate of LYVE-1 in the paracancer tissues of LVSI patients was statistically higher than that of those without LVSI（P＜0.05）. The positive expression rate of Prox-1 of LVSI and advanced patients increased in the paracancer tissues, compared with those without  LVSI and the early patients, the difference was statistically significant（P＜0.05）. ②Realtime RT-PCR and Western blotting detection: compared with the paracancer tissues without lymph node metastasis, the expression of Prox-1 protein in the lymph node metastasis group was 1.250 0±0.008 2（P＜0.05） and the expression of LYVE-1 protein was 1.860 0±0.012 4（P＜0.05）. Compared with that in the paracancer tissues, the expression level of Prox-1 mRNA in the tumor tissues in the lymph node metastasis group was 0.693+0.083（P＜0.05） and the expression level of LYVE-1 mRNA was 0.42±0.16（P＜0.05）. Conclusions: LYVE-1 and Prox-1 may be potential markers for lymph node metastasis in endometrial carcinoma. The results also suggest that the generation of lymphatic vessels in paracancer tissue is related to lymph node metastasis.

Key words: LYVE-1, Prox-1, Endometrial carcinoma, Clinicopathology, Blotting, portein, Polymerase chain reaction